Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Multicenter, Randomized Phase III Study of the Telomerase Vaccine, GV1001 Administered After Curative Intent Chemo-radiotherapy in Patients With Inoperable Stage III Non-small Cell Lung Cancer Compared to Best Supportive Care

NCT01579188 is registered in ClinicalTrials.gov with Kael-GemVax Co., Ltd. as lead sponsor.

NCT NCT01579188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01579188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Multicenter, Randomized Phase III Study of the Telomerase Vaccine, GV1001 Administered After Curative Intent Chemo-radiotherapy in Patients With Inoperable Stage III Non-small Cell Lung Cancer Compared to Best Supportive Care
Lead sponsor
Kael-GemVax Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2012
Completion date
May 31, 2016
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

inoperable stage iii non-small cell lung cancer